Sequenom
Clinical trials sponsored by Sequenom, explained in plain language.
A molecular diagnostics company known for prenatal testing, now part of Labcorp.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New blood test aims to sharpen prostate cancer detection Results expected Mar 2027 (estimated)
- Simple blood test may spot preeclampsia risk before symptoms appear Results expected Jun 2027 (estimated)
-
Can a simple blood test reliably screen for fetal genetic conditions?
Knowledge-focused CompletedThis study follows 20,000 pregnant women who took a non-invasive prenatal test (NIPT) to see how accurately the test predicts fetal genetic conditions. Researchers will compare the test results with actual pregnancy outcomes to measure its sensitivity, specificity, and predictive…
Sponsor: Sequenom, Inc. • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Blood test may guide rheumatoid arthritis treatment decisions
Knowledge-focused CompletedThis study looks at whether a blood test called Vectra can help doctors make better treatment choices for people with rheumatoid arthritis (RA). The test gives a score from 1 to 100 to show how active the disease is. About 1500 adults with RA will be split into two groups: one wh…
Sponsor: Sequenom, Inc. • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC